×
The COVID-19 VaccinE Response and Co-Administration in Rheumatology Patients (COVER-CoAd)
https://clinicaltrials.gov/ct2/show/NCT05543642

Mar 17th, 2023 - The COVID-19 pandemic, caused by the coronavirus SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), has infected a substantial portion of the world population, leading to millions of deaths since its first description in December of 2019. Recently, several SARS-CoV-2 vaccines have shown excellent efficacy and tolerability in the general population and have been either fully approved ...

Genomics, Environmental Factors and Social Determinants of Cardiovascular Disease in African-Americans Study (GENE-FORECAST): Prospective COVID-19 Natural History Study
https://clinicaltrials.gov/ct2/show/NCT05484882

Mar 17th, 2023 - STUDY DESCRIPTION The objective is to conduct a prospective natural history study of Coronavirus disease 2019 (COVID-19) among a community-based cohort of African Americans enrolled in GENE-FORECAST for whom we have comprehensive psychosocial, clinical, and genetic data collected at baseline. Participants will be invited to take part in a 20-minute computer-assisted telephone interview (CATI) o...

Preserving Compassionate End of Life Care in the Pandemic
https://clinicaltrials.gov/ct2/show/NCT04602520

Mar 16th, 2023 - This is a mixed-methods formative program evaluation of the adaptations necessitated by the pandemic to the 3 Wishes Project. The adaptations will be studied as implemented in 3 acute care units at St. Joseph's Healthcare Hamilton (medical stepdown unit, medical-surgical ICU and the COVID-19 unit) during the 2020 SARS-CoV-2 pandemic. End-of-life care for patients dying in hospital is profoundly...

Pain in Pediatric Dentistry - a Grounded Theory Study on the Experiences of Dental Professionals and Students
https://clinicaltrials.gov/ct2/show/NCT04643951

Mar 16th, 2023 - BACKGROUND Pain in conjunction with dental treatment should be avoided, especially when treating children. Many dental procedures may result in procedural and/or postoperative pain. There is a well-documented relationship between perceived pain during dental treatment, and the development of dental fear and anxiety. This may lead to suffering for the patient, avoidance of dental care, and incre...

SARS-COV2 Pandemic Serosurvey in a Rare Disease Population
https://clinicaltrials.gov/ct2/show/NCT04609085

Mar 14th, 2023 - It has been demonstrated that respiratory virus outbreaks and pandemics, such as influenza, SARS, MERS, and now the newly emerged SARS-COV2 virus, have a major impact on morbidity and mortality worldwide, as well as having devastating global economic and societal impact. During these outbreaks it is critical to gain a rapid understanding of the exposures and immunity in the general population. ...

Addressing Vaccine Hesitancy and Increasing COVID-19 Vaccine Uptake Among African American Young Adults in the South
https://clinicaltrials.gov/ct2/show/NCT05490329

Mar 14th, 2023 - The study staff will recruit and enroll 360 AA-YA from communities in Alabama, Georgia, and North Carolina. After collecting informed consent, participants will be randomized using block randomization to the control condition or TT-C (remote), each with a balanced 180 participants (N=360). The standard of care (SOC) control will be the provision of COVID vaccine materials from the CDC. After sc...

COVID-19 in People With Primary Ciliary Dyskinesia
https://clinicaltrials.gov/ct2/show/NCT04602481

Mar 13th, 2023 - Background: The current pandemic of Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 virus is a public health emergency of international concern. The severity of COVID-19 ranges from asymptomatic to severe. Patients with chronic lung disease such as primary ciliary dyskinesia (PCD) are thought to be at increased risk, but no data support this. Disease course and optimal treatment strate...

Women s Health Awareness Community Resiliency, Environmental Action and Collaborations for Health (REACH) Equity
https://clinicaltrials.gov/ct2/show/NCT04983251

Mar 10th, 2023 - This is a cross-sectional population-based survey designed within a syndemic framework to characterize the impacts of the COVID-19 pandemic on women in under-studied, under-represented, and underreported (U3) populations. We hypothesize that U3 women are experiencing and will have experienced a worsening of mental, physical, and socio-economic status as a result of the COVID-19 pandemic and tha...

Validation of Patient E-tool to Measure Systemic Lupus Activity
https://clinicaltrials.gov/ct2/show/NCT05763225

Mar 10th, 2023 - Systemic Lupus Erythematosus (SLE) is a rare and chronic autoimmune disease. Disease activity (DA) is marked by remissions, spontaneous relapses or induced by therapeutic modifications. SLE exposes to serious complications requiring close medical follow-up, but flares cannot be predicted and often do not coincide with medical consultations. SLE DA is measured during a consultation using the SLE...

COVID-19 Experiences in the SELF Cohort
https://clinicaltrials.gov/ct2/show/NCT05369611

Mar 10th, 2023 - Study Description: This cross-sectional study will be an add-on to the Study of Environment, Lifestyle and Fibroids (SELF) (Protocol Number: 10-E-N044). SELF is a prospective cohort study of fibroid development. From November 2010 to December 2012, the study enrolled a volunteer sample recruited from Detroit, MI and surrounding areas of approximately 1,700 African-American women ages 23-35 with...

Procedural Motor Memory in Long COVID-19
https://clinicaltrials.gov/ct2/show/NCT05746624

Mar 10th, 2023 - This study will objectively test procedural motor memory in a group of people with ongoing symptoms following recovery from acute COVID-19 infection. Primary Objective: We will use a keyboard typing task to investigate procedural memory formation (primary endpoint measure) in the context of COVID-19 infection. We have two primary comparisons using the same outcome measure To compare procedural ...

Immunogenicity and Safety of COVID-19 Vaccine in Population Aged 18 Years and Above
https://clinicaltrials.gov/ct2/show/NCT05663086

Mar 10th, 2023 - Subjects will receive 1 dose or 2 doses of LYB001, according to the immunization schedule of 0 day or 0, 28 days. The adverse events within 28 days after each vaccination will be observed. In addition, blood samples will be collected on day 0 before vaccination,and on day 7, 14, 28 and month 3, 6, 12 after full vaccination. Serum antibody levels, cellular immune responses will be analyzed to ev...

Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTS
https://clinicaltrials.gov/ct2/show/NCT05633407

Mar 10th, 2023 - The study aims to investigate the safety, tolerability, efficacy, pharmacodynamics (PD), pharmacokinetics (PK), and immunogenicity of efgartigimod compared to placebo in participants with post-COVID-19 postural orthostatic tachycardia syndrome (POTS) (post-COVID-19 POTS). Efgartigimod may be a viable treatment option for individuals diagnosed with post-COVID-19 POTS because it has been shown to...

Study to Determine the Response to COVID-19 Vaccination and Prevalence of COVID-19 in Subjects With Chronic Liver Disease
https://clinicaltrials.gov/ct2/show/NCT05669677

Mar 10th, 2023 - Study Description: The goals of this study are to assess the response to COVID vaccination in patients with chronic liver disease. Secondary goals are to evaluate the durability of antibody response against SARS-COV-2 and if SARS-COV-2 seropositivity is associated with reactivation or worsening of chronic hepatitis B. Hypothesis: Subjects with cirrhosis will have poorer response to COVID vaccin...

Natural History, Disease Progression, and Long-Term Neurologic Sequelae of Ebola Virus Disease (EVD) Survivors in PREVAIL III
https://clinicaltrials.gov/ct2/show/NCT05494801

Mar 10th, 2023 - Study Description: The long-term neurological sequelae of Ebola virus disease are not welldescribed. Through the PREVAIL III (PIII) Ebola Natural History Study, a Neurology Substudy was undertaken to better understand the long-term neurologic sequelae of EVD, with 5 years of follow up planned. Unfortunately, due to the COVID-19 pandemic beginning in early 2020, the final study evaluations of th...

A Study to Learn About the Study Medicines (Nirmatrelvir Plus Ritonavir) in People Aged 12 Years or Older With COVID-19 and a Compromised Immune System
https://clinicaltrials.gov/ct2/show/NCT05438602

Mar 10th, 2023 - The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called Nirmatrelvir/Ritonavir) for the possible treatment of COVID-19. Patients with COVID-19 who have more difficulty in fighting against infections have a higher chance of severe illness. Such patients may benefit from longer treatment durations compared to the standard treatment regimen. The st...

Distress Associated With Coronavirus Disease 2019 and Telehealth on Supportive Care Patients With Advanced Cancer
https://clinicaltrials.gov/ct2/show/NCT05058339

Mar 10th, 2023 - PRIMARY OBJECTIVES: I. Assess advanced cancer patients' level of distress due to the COVID-19 pandemic. II. Assess patients' overall preference towards palliative telemedicine vs in person visits during the COVID-19 pandemic. SECONDARY OBJECTIVES: I. Assess associations between patient characteristics and perceptions of overall distress due to the COVID-19 pandemic. II. Assess associations betw...

EU Secondary Data Post-Authorisation Safety Study of AZD1222
https://clinicaltrials.gov/ct2/show/NCT05126992

Mar 10th, 2023 - This retrospective study based on electronic heath records will evaluate the incidence and relative risk of safety concerns and adverse events of special interest (AESIs) following immunisation by AZD1222 in the real-world setting. The primary study objectives are to (1) describe baseline characteristics of all individuals in the matched population over the study period; (2) describe, among sub...

Tobacco Use and the Risk of COVID-19 and Adverse Outcomes
https://clinicaltrials.gov/ct2/show/NCT05321433

Mar 10th, 2023 - The coronavirus disease (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused more than 470 million confirmed cases of COVID-19, and more than 6 million deaths around the world by March 25, 2022 (WHO, 2022). Since the beginning of the COVID-19 pandemic, several factors have been attributed to increasing the risk of infection and adverse outcomes...

Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial
https://clinicaltrials.gov/ct2/show/NCT05361811

Mar 10th, 2023 - Background: RASopathies are a group of neurodevelopmental genetic conditions caused by mutations affecting components within the RAS-map kinase (RAS-MAPK) cellular signaling pathway. Caregivers of children with a RASopathy are faced with numerous challenges related to the physical, cognitive, and behavioral symptoms associated with their child s condition. The use of virtual interventions has b...